Abstract:Objective: Noninvasive detection of molecular status of astrocytoma is of great clinical significance for predicting therapeutic response and prognosis. We aimed to evaluate whether morphological MRI (mMRI), SWI, DWI, and DSC-PWI could predict Ki-67 labeling index (LI), ATRX mutation, and MGMT promoter methylation status in IDH mutant (IDH-mut) astrocytoma. Methods: We retrospectively analyzed mMRI, SWI, DWI, and DSC-PWI in 136 patients with IDH-mut astrocytoma.The features of mMRI and intratumoral susceptibility signals (ITSS) were compared using Fisher exact test or chi-square tests. Wilcoxon rank sum test was used to compare the minimum ADC (ADCmin), and minimum relative ADC (rADCmin) of IDH-mut astrocytoma in different molecular markers status. Mann-Whitney U test was used to compare the rCBVmax of IDH-mut astrocytoma with different molecular markers status. Receiver operating characteristic curves was performed to evaluate their diagnostic performances. Results: ITSS, ADCmin, rADCmin, and rCBVmax were significantly different between high and low Ki-67 LI groups. ITSS, ADCmin, and rADCmin were significantly different between ATRX mutant and wild-type groups. Necrosis, edema, enhancement, and margin pattern were significantly different between low and high Ki-67 LI groups. Peritumoral edema was significantly different between ATRX mutant and wild-type groups. Grade 3 IDH-mut astrocytoma with unmethylated MGMT promoter was more likely to show enhancement compared to the methylated group. Conclusions: mMRI, SWI, DWI, and DSC-PWI were shown to have the potential to predict Ki-67 LI and ATRX mutation status in IDH-mut astrocytoma. A combination of mMRI and SWI may improve diagnostic performance for predicting Ki-67 LI and ATRX mutation status. Clinical relevance statement: Conventional MRI and functional MRI (SWI, DWI, and DSC-PWI) can predict Ki-67 expression and ATRX mutation status of IDH mutant astrocytoma, which may help clinicians determine personalized treatment plans and predict patient outcomes. Key points: • A combination of multimodal MRI may improve the diagnostic performance to predict Ki-67 LI and ATRX mutation status. • Compared with IDH-mutant astrocytoma with low Ki-67 LI, IDH-mutant astrocytoma with high Ki-67 LI was more likely to show necrosis, edema, enhancement, poorly defined margin, higher ITSS levels, lower ADC, and higher rCBV. • ATRX wild-type IDH-mutant astrocytoma was more likely to show edema, higher ITSS levels, and lower ADC compared to ATRX mutant IDH-mutant astrocytoma.

BI-06 * ATRX LOSS IN CHINESE ADULT DIFFUSE ASTROCYTOMAS CORRELATES WITH IDH1 AND TP53 MUTATION AND PREDICTS BETTER OUTCOME IN TP53 MUTATED PATIENTS

ATRX loss in adult supratentorial diffuse astrocytomas correlates with p53 over expression and IDH1 mutation and predicts better outcome in p53 accumulated patients.

Primary Astrocytic Tumours and Paired Recurrences Have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss

Apoptosis in Supratentorial Astrocytomas and Expression of Apoptosis Related Gene P53 and Bcl-2

Alpha thalassemia/mental retardation X-linked (ATRX) protein expression in human pituitary neuroendocrine tumours and its reported correlation to prognosis and clinical outcomes: A systematic review.

ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma

ATRX Loss Promotes Tumor Growth and Impairs Nonhomologous End Joining DNA Repair in Glioma

Prediction of Ki-67 labeling index, ATRX mutation, and MGMT promoter methylation status in IDH-mutant astrocytoma by morphological MRI, SWI, DWI, and DSC-PWI

Integrated genomic and transcriptomic analysis identified <i>KRT18</i> mutation and <i>MTAP</i> loss as key genetic alterations related to the prognosis of astrocytoma and glioblastoma.

Integrated genomic and transcriptomic analysis identified KRT18 mutation and MTAP loss as key genetic alterations related to the prognosis of astrocytoma and glioblastoma.

Not All 1p/19q Non-Codeleted Oligodendroglial Tumors Are Astrocytic

TP53 Mutation vis-à-vis Malignant Progression in Astrocytoma WHO Grade II

Multicenter clinical radiomics-integrated model based on [<SUP>18</SUP>F]FDG PET and multi-modal MRI predict ATRX mutation status in IDH-mutant lower-grade gliomas

Knockdown of ATRX enhances radiosensitivity in glioblastoma

Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1 R132H mutation and may predict better prognosis among glioblastomas without the IDH1 mutation and ATRX loss.

Correlation between IDH, ATRX, and TERT promoter mutations in glioma

Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis

IDH1, ATRX, p53, and Ki67 Expression in Glioblastoma patients: Their Clinical and Prognostic Significance—A Prospective Study

Epco-21. Elucidating The Functional Relevance Of Atrx-Deficiency In H3.3-G34-Mutant Diffuse Hemispheric Glioma

Chromatin-regulating genes are associated with postoperative prognosis and isocitrate dehydrogenase mutation in astrocytoma

Insights from a Multicenter Study on Adult H3 K27M-Mutated Glioma: Surgical Resection's Limited Influence on Overall Survival, ATRX as Molecular Prognosticator